Target intelligence / Profile preview

GAR1 ribonucleoprotein (GAR1)

Target
GAR1
Molecular classification
Small nucleolar ribonucleoprotein (snoRNP) component, RNA-binding protein, Non-ribosomal nucleolar protein, H/ACA snoRNP protein family
01

Overview

GAR1 ribonucleoprotein is a conserved, glycine- and arginine-rich nucleolar protein that forms part of the **H/ACA snoRNP complex**, which is essential for **rRNA pseudouridylation** and **ribosome biogenesis** in eukaryotic cells[3][4][7][1]. It facilitates substrate RNA placement, enhances the catalytic activity of Cbf5 (the pseudouridine synthase), and is necessary for the correct processing of pre-rRNA substrate and 18S rRNA formation[2][5][1]. GAR1 associates with other core proteins (NAP57/dyskerin/Cbf5, NHP2, and NOP10), and plays roles in telomerase holoenzyme assembly and function, with essentiality reflected by impaired cell growth in its absence[1][3][7][8]. GAR1's dysfunction is mapped to diseases involving ribosomal defects and telomerase activity, including Fanconi anemia and spinal muscular atrophy[3]. No known drugs interact directly with GAR1, nor is it a clinical biomarker or therapeutic target in current data.

Other names
Gar1p (in yeast)H/ACA ribonucleoprotein complex subunit 1GAR1
02

Biological functions

Ribosome biogenesisrRNA pseudouridylation (catalysis and substrate placement)rRNA processing in the nucleolus and cytosolTelomere maintenance (component of telomerase complex)RNA binding and stabilization
03

Disease associations

Fanconi anemia, complementation group QSpinal muscular atrophyPotential links to other ribosomopathies (defects in rRNA processing), due to its essential role

Beyond the preview

Go deeper on GAR1 ribonucleoprotein (GAR1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAR1 ribonucleoprotein (GAR1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call